SubHero Banner

Keytruda® (pembrolizumab) – New indication

July 31, 2019 - Merck announced the FDA approval of Keytruda (pembrolizumab), for the treatment of patients with recurrent locally advanced or metastatic squamous cell carcinoma of the esophagus whose tumors express PD-L1 [Combined Positive Score (CPS) ≥ 10] as determined by an FDA-approved test, with disease progression after one or more prior lines of systemic therapy.

Download PDF